Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Verastem, Inc. (NASDAQ:VSTM – Get Rating) have received a consensus recommendation of “Moderate Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $5.00.

A number of equities research analysts have commented on the company. StockNews.com began coverage on Verastem in a report on Monday, January 16th. They issued a “hold” rating for the company. HC Wainwright reduced their target price on Verastem from $5.00 to $3.00 and set a “buy” rating on the stock in a research note on Monday, November 7th.

Hedge Funds Weigh In On Verastem

Several large investors have recently added to or reduced their stakes in VSTM. Synovus Financial Corp increased its position in Verastem by 10.2% during the first quarter. Synovus Financial Corp now owns 108,000 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 10,000 shares during the last quarter. Charles Schwab Investment Management Inc. increased its stake in Verastem by 2.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 460,493 shares of the biopharmaceutical company’s stock worth $650,000 after acquiring an additional 11,090 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Verastem by 45.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 47,100 shares of the biopharmaceutical company’s stock worth $54,000 after purchasing an additional 14,800 shares during the period. Arete Wealth Advisors LLC acquired a new position in shares of Verastem in the 4th quarter valued at about $7,748,120,000. Finally, JPMorgan Chase & Co. increased its position in Verastem by 23.8% during the 1st quarter. JPMorgan Chase & Co. now owns 103,057 shares of the biopharmaceutical company’s stock worth $145,000 after purchasing an additional 19,837 shares in the last quarter. 60.59% of the stock is currently owned by hedge funds and other institutional investors.

Verastem Stock Performance

NASDAQ VSTM opened at $0.52 on Wednesday. The business’s 50-day moving average price is $0.54 and its 200 day moving average price is $0.64. The company has a quick ratio of 4.97, a current ratio of 4.97 and a debt-to-equity ratio of 0.39. The firm has a market cap of $109.18 million, a P/E ratio of -1.33 and a beta of 0.81. Verastem has a 52-week low of $0.29 and a 52-week high of $2.13.

About Verastem

(Get Rating)

Verastem, Inc is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.